Search Results - "Lauand, Felipe"

The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM by Renard, Eric, Ikegami, Hiroshi, Daher Vianna, André Gustavo, Pozzilli, Paolo, Brette, Sandrine, Bosnyak, Zsolt, Lauand, Felipe, Peters, Anne, Pilorget, Valerie, Jurišić‐Eržen, Dubravka, Kesavadev, Jothydev, Seufert, Jochen, Wilmot, Emma G.

“…Aims To describe glycaemic control and diabetes management in adults with type 1 diabetes (T1DM), in a real‐life global setting. Materials and Methods Study of…”
Get full text

1095-P: Early Hypoglycemia after Initiation of Second-Generation Basal Insulin (BI) Analogs: Patient Characteristics and Clinical Outcomes by HARRIS, STEWART B., BERARD, LORI, WESTERBACKA, JUKKA, BOSNYAK, ZSOLT, MELAS-MELT, LYDIE, LAUAND, FELIPE, BAILEY, TIMOTHY S., KHUNTI, KAMLESH

“…Titration following initiation of BI tends to occur in the first 8-12 weeks. At this time, patients may be at risk of experiencing hypoglycemia, which itself…”
Get full text

781-P: Efficacy and Safety of Switching to iGlarLixi from Twice-Daily (BID) Premixed Insulin (PI) Administration in People with Type 2 Diabetes (T2D)-Subanalysis of Soli-SWITCH Study by Haluzik, Martin, Min, Kyungwan, Cypryk, Katarzyna, Alvarez, Agustina, Lauand, Felipe, Ren, Yan, Bakiner, Okan

“…Introduction & Objective: iGlarLixi is a once-daily injectable fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide. This sub-analysis of…”
Get full text

780-P: Soli-SWITCH-Efficacy and Safety of Switching to iGlarLixi from Premixed Insulins (PI) in People with Type 2 Diabetes (T2D) by Haluzik, Martin, Cypryk, Katarzyna, Alvarez, Agustina, Lauand, Felipe, Dit Genti, Valerie Corp, Bakiner, Okan, Lim, Soo

“…Introduction & Objective: iGlarLixi, a once-daily injectable fixed-ratio combination of insulin glargine 100 U/mL + lixisenatide, has demonstrated improved…”
Get full text

Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials by Yang, Wenying, Guo, Xiaohui, Lauand, Felipe, Li, Lingyu, Fang, Hexin, Du, Qin, Kang, Lei

“…Aim To evaluate the effect of age and disease duration on the efficacy and safety of iGlarLixi versus insulin glargine 100 units/ml (iGlar) or lixisenatide…”
Get full text

765-P: Efficacy and Safety of Switching to iGlarLixi from Premixed Insulin (PI) in South Korean People Living with Type 2 Diabetes (T2D)-Subanalyses of Soli-SWITCH Study by Lim, Soo, Haluzik, Martin, Yun, Jae-seung, Lee, Jihyun, Kim, Sangyong, Alvarez, Agustina, Lauand, Felipe, Ren, Yan, Yoo, Soon Jib

“…Introduction & Objective: iGlarLixi is a once-daily injectable fixed-ratio combination of insulin glargine 100 U/mL + lixisenatide and may be a simplified…”
Get full text

Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials by Giorgino, Francesco, Guja, Cristian, Aydın, Hasan, Lauand, Felipe, Melas-Melt, Lydie, Rosenstock, Julio

“…•SGLT2is and GLP-1 RAs are recommended for T2D and CV disease/CKD/heart failure.•Pooled results from three iGlarLixi studies of adults with T2D with/without…”
Get full text

iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan‐L‐CN study by Yuan, Xiaoyong, Li, Dongmei, Wang, Kun, Lauand, Felipe, Zhang, Minlu, Fang, Hexin, Du, Qin, Kang, Lei, Alvarez, Agustina, Guo, Xiaohui

“…Aim To compare the effects of iGlarLixi versus insulin glargine 100 U/mL (iGlar) on residual hyperglycaemia in Chinese people with uncontrolled type 2 diabetes…”
Get full text

Impact of X-Ray Exposure From Computed Tomography on Wearable Insulin Delivery Devices by Dong, Frank, Johnson, Paul, Fong, Grant, Nguyen, Alex, Lauand, Felipe, Vienneau, Todd

“…Background: To investigate the impact of radiation exposure from a computed tomography (CT) scanner on the functional integrity of a wearable insulin delivery…”
Get full text

1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation by Giorgino, Francesco, Lauand, Felipe, Servera, Soraly, Li, Xuan, Taybani, Zoltán, Cheng, Alice YY, Fonseca, Vivian, Tebaibia, Amar, Anaforoglu, Inan

“…Introduction and Objective: Basal bolus insulin (BBI) therapy is associated with body weight (BW) gain and an increased risk of hypoglycemia, further…”
Get full text

1869-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)-The SoliD Randomized Controlled Trial by Liu, Ming, Gu, Weijun, Chen, Li, Li, Yanbing, Kuang, Hongyu, Du, Jianling, Alvarez, Agustina, Lauand, Felipe, Souhami, Elisabeth, Zhang, Jiewen, Xu, Weiya, Du, Qin, Mu, Yiming

“…Introduction and Objective: SoliD (NCT05413369) compared the efficacy and safety of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL +…”
Get full text

1880-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin-A Systemic Literature Review and Network Meta-analysis by Home, Philip, Lauand, Felipe, Djaballah, Khier, Bourhis, Francois, Li, Xuan, Hafidh, Khadija, Mehta, Roopa, Faraoun, Khadra, Anaforoglu, Inan, Pourrahmat, Mir-Masoud

“…Introduction and Objective: The objective of this systematic review and network meta-analysis (NMA) was to estimate the relative treatment effect of iGlarLixi…”
Get full text

Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials by Danne, Thomas, Matsuhisa, Munehide, Sussebach, Christian, Goyeau, Harmonie, Lauand, Felipe, Niemoeller, Elisabeth, Bolli, Geremia B.

“…Severe hypoglycaemia (SH) remains a challenge to people with type 1 diabetes (T1DM), and new‐generation basal insulins may improve patient outcomes. This post…”
Get full text

The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial by Liu, Ming, Gu, Weijun, Chen, Li, Li, Yanbing, Kuang, Hongyu, Du, Jianling, Alvarez, Agustina, Lauand, Felipe, Souhami, Elisabeth, Zhang, Jiewen, Xu, Weiya, Du, Qin, Mu, Yiming

“…Aim To compare the efficacy and safety of a fixed‐ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with premixed insulin, insulin…”
Get full text

775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis by MUNSHI, MEDHA, RITZEL, ROBERT, MCCRIMMON, RORY J., HRAMIAK, IRENE, LAUAND, FELIPE, MELAS-MELT, LYDIE, SOUHAMI, ELISABETH, ROSENSTOCK, JULIO

“…For older adults (>65 years) with type 2 diabetes (T2D), iGlarLixi can be a simple and effective therapeutic option. We aimed to identify factors associated…”
Get full text

773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis by GIORGINO, FRANCESCO, GUJA, CRISTIAN, DAVIES, MELANIE J., AYDIN, HASAN, LAUAND, FELIPE, SOUHAMI, ELISABETH, MELAS-MELT, LYDIE, ARODA, VANITA R., ROSENSTOCK, JULIO

“…SGLT2i therapy is recommended for people with T2D, especially those at high cardiovascular risk or with chronic kidney disease or heart failure, due to its…”
Get full text

788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi by CHENG, ALICE Y., FRIAS, JUAN P., GUJA, CRISTIAN, LAUAND, FELIPE, MELAS-MELT, LYDIE, ALVAREZ, AGUSTINA, SOUHAMI, ELISABETH, ROSENSTOCK, JULIO

“…This post-hoc, pooled analysis of 4 trials aimed to identify factors associated with achieving target HbA1c <7.0% in people with type 2 diabetes (T2D) treated…”
Get full text

800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial by HALUZIK, MARTIN, FRIAS, JUAN P., CHENG, ALICE Y., AL-SOFIANI, MOHAMMED, LAUAND, FELIPE, MELAS-MELT, LYDIE, SOUHAMI, ELISABETH, ROSENSTOCK, JULIO

“…We aimed to evaluate derived Time in Range (dTIR) and identify predictors for achieving HbA1c and dTIR targets after commencing iGlarLixi in people with type 2…”
Get full text

799-P: Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis by HRAMIAK, IRENE, FRIAS, JUAN P., AYDIN, HASAN, LAUAND, FELIPE, MELAS-MELT, LYDIE, SOUHAMI, ELISABETH, HALUZIK, MARTIN, ROSENSTOCK, JULIO

“…This post-hoc, pooled analysis of 3 randomized controlled trials aimed to identify factors associated with achieving a derived Time in Range (dTIR) ≥70% at the…”
Get full text

iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis by Guo, Xiaohui, Yang, Wenying, Zhang, Junqing, Dong, Xiaolin, Liu, Ming, Gu, Shenghong, Lauand, Felipe, Li, Lingyu, Huang, Qiong, Kang, Lei, Souhami, Elisabeth

“…Aim To evaluate the efficacy of iGlarLixi in the Asian Pacific (AP) population with type 2 diabetes (T2D) using derived time‐in‐ranges calculated from…”
Get full text